H.R. 3539 · 114th Congress

Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015

Stage
In committee
Introduced
2015-09-17
Latest action
2015-09-17 · Introduced in House

Summary

Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015

This bill amends the Internal Revenue Code to allow tax credits for 50% of the clinical testing expenses for: (1) infectious disease products that are intended to treat a serious or life-threatening infection, including one caused by an antibacterial or antifungal resistant pathogen or a qualifying pathogen listed by the Department of Health and Human Services as having the potential to pose a serious threat to public health; and (2) in-vitro diagnostic devices that identify in less than four hours the presence, concentration, or characteristics of a serious or life-threatening infection.